This analysis examines the historical and forecast performance for Solvay in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Solvay's performance against key rivals in the prescription pharmaceutical sector
See how sales growth driven by increased penetration of the US dyslidemia market will be offset by a growing generic threat and poor R&D productivity
Learn how Solvay plans to continue raising its operating profit margin, already improved by an increased pharma focus, by pursuing efficiency savings
Please Note: This product is delivered as a zip file